DOI: 10.1016/j.mito.2024.101877 Enhanced Mitochondrial Mrs2-Mg2+ Signaling Drives Mitochondrial Dysfunction in Pulmonary Arterial Hypertension Rats by Ruo-Nan Chen, Xue-Qin Weng, Yan Yan, Qin-Ye Chen, Yi-Chen Lin, Lan Liu, Xiao-Ling Zhuang, Long-Xin Gui, James S.K
Who Should Not Use GLP-1 Medications According to standard clinical guidelines and prescribing information, GLP-1 medications may not be appropriate for individuals who: Have a personal or family history of medullary thyroid carcinoma Have multiple endocrine neoplasia syndrome type 2 Have a history of pancreatitis Have severe gastrointestinal disease (gastroparesis, inflammatory bowel disease) Are pregnant, planning to become pregnant, or breastfeeding Have a history of severe allergic reactions to semaglutide, tirzepatide, or any inactive ingredients This is not a replacement for prescribed medical treatment for any health condition
Annals of the New York Academy of Sciences, 1201, 96103
FDA Phasing Out Compounded GLP-1 Medications By the end of May 2025, compounding pharmacies will no longer be permitted to produce GLP-1 medications such as semaglutide (Ozempic, Wegovy)
If you've had a prolonged treatment interruption, contact your healthcare team for advice on re-titration
)
